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Human APOBEC3 (A3) proteins are host-encoded intrinsic restriction factors that inhibit the replication of
many retroviral pathogens. Restriction is believed to occur as a result of the DNA cytosine deaminase activity
of the A3 proteins; this activity converts cytosines into uracils in single-stranded DNA retroviral replication
intermediates. A3 proteins are also equipped with deamination-independent means to restrict retroviruses
that work cooperatively with deamination-dependent restriction pathways. A3 proteins substantially bolster
the intrinsic immune system by providing a powerful block to the transmission of retroviral pathogens; how-
ever, most retroviruses are able to subvert this replicative restriction in their natural host. HIV-1, for instance,
evades A3 proteins through the activity of its accessory protein Vif. Here, we summarize data from recent A3
structural and functional studies to provide perspectives into the interactions between cellular A3 proteins
and HIV-1 macromolecules throughout the viral replication cycle.All living creatures from bacteria to humans have evolved clever
defense mechanisms to protect themselves against infectious
enemies. Conversely, infectious agents such as viruses often
combat these defense mechanisms by hijacking host metabolic
pathways to perpetuate their life cycles. The mammalian innate
immune system has evolved multiple cellular restriction factors
that impair the rapid replication of retroviruses. There are at least
nine distinct intrinsic and innate restriction factors in mammals:
Fv1, Lv1, Lv2, BST-2/tetherin, Trim5a, Mov10, SAMHD1, MX2,
and APOBEC3 (Best et al., 1996; Goujon et al., 2013; Hatziioan-
nou et al., 2003; Kane et al., 2013; Laguette et al., 2011; Neil
et al., 2008; Schmitz et al., 2004; Sheehy et al., 2002; Stoye
et al., 1995; Stremlau et al., 2004; Wang et al., 2010). Their broad
activity against endogenous and exogenous retroviruses make
them essential components of the innate immune system and
their expression impairs species-specific and interspecies retro-
viral transmission (Esnault et al., 2006; Harris et al., 2003; Schu-
macher et al., 2008).
In 1998, Madani and Kabat (1998) and Simon et al. (1998) pro-
posed that a cellular protein, present in some cell types, is
involved in restricting the replication of HIV-1 that lacks the viral
infectivity factor (Vif) accessory protein. Four years later, Sheehy
et al. (2002) were the first to identify CEM15 as the host factor
responsible for rendering some cells nonpermissive upon dele-
tion of the vif gene from HIV-1 (HIV-1Dvif). The authors
concluded that CEM15 is a specific and efficient inhibitor
of HIV-1Dvif infectivity. Further characterization determined
CEM15 as an enzyme with deoxycytidine deaminase activity
(Harris et al., 2002, 2003). The inhibitory properties of CEM15
is dependent on the direct deamination of DNA cytosine mole-
cules in the minus-strand of HIV-1 proviral DNA (Harris et al.,
2003; Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al.,
2003). Due to its structural and functional similarities with other
cytidine deaminase enzymes, such as APOBEC1 (A1) and
APOBEC2 (A2), it was deceivingly renamed as human apolipo-
protein B mRNA-editing, enzyme-catalytic polypeptide like-3 G668 Structure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reserved(A3G). In contrast to A1, A3G does not deaminate RNA (Harris
et al., 2002). In Figure 1, the deaminase-dependent and
deaminase-independent antiviral activities of A3 proteins are
summarized.
After the initial discovery of A3G, many other family members
were identified in humans and other mammalian species (Conti-
cello et al., 2005; Jarmuz et al., 2002). Investigation of human A3
proteins revealed that humans have seven A3 genes (A3A, A3B,
A3C, A3D, A3F, A3G, A3H), all of which are located within a
150 kb region on chromosome 22 (Conticello et al., 2005; Jarmuz
et al., 2002). Structural and sequence analysis of A3 proteins
indicate that despite high sequence similarities, their physiolog-
ical activities and domain organizations vary across species
(LaRue et al., 2008). Some A3 proteins contain only a single
zinc (Z)-containing deaminase domain (e.g., A3A, A3C, and
A3H), whereas others (e.g., A3B, A3D, A3F, and A3G) have
two Z domains (Bogerd et al., 2007; Jarmuz et al., 2002)
(Figure 2A). Based on sequence analysis, the Z domains are
divided into three categories: Z1 (A3A and the C-terminal domain
[CTD] of A3B and A3G), Z2 (A3C, both domains of A3D and A3F
and the N-terminal domain [NTD] of A3B and A3G), and Z3 (A3H)
(LaRue et al., 2009).
Due to its potency as an antiretroviral restriction factor and its
importance for HIV-1 infection, A3G is the best-characterized A3
family protein (Chaipan et al., 2013). A3G has two catalytic do-
mains, yet only the CTD is enzymatically active (Hache´ et al.,
2005; Navarro et al., 2005). The NTD is responsible for RNA bind-
ing, processivity and viral encapsidation (Feng and Chelico,
2011; Huthoff and Malim, 2007; Huthoff et al., 2009). Although
the A3G-NTD lacks enzymatic activity, it physically interacts
with HIV-1 proteins and inhibits the infectivity of the virus without
editing any residues on the single-stranded DNA intermediate
(Cen et al., 2004; Luo et al., 2007; Wang et al., 2012). Both of
these domains in A3 proteins contribute to the antiretroviral ac-
tivity of the protein and provide enhanced restriction during the
viral replication cycle (Langlois et al., 2005; Navarro et al.,
Figure 1. Antiviral Activities of APOBEC3 Proteins during HIV-1 Infection
In the absence of HIV-1 Vif, APOBEC3proteins interact with viral macromolecules atmultiple stages of the HIV-1 life cycle to inhibit replicative processes resulting
in nonproductive infection. In the target T cells, (1) a HIV-1Dvif virion with encapsidated A3G binds to coreceptors and receptors on the cell surface and traffics to
the endosome. (2) The HIV-1 gp160 catalyzes the fusion of the viral and endosomal membranes to allow the release of its contents into the cytoplasm. (3) Reverse
transcription (RT) occurs while the capsid is uncoating. Note: uncoating and reverse transcription are drawn as separate steps only for clarity in the figure. A3
oligomers bind the viral RNA and produce a roadblock to reverse transcriptase movement along the template, resulting in a reduction of viral DNA synthesis. The
dissociation of A3 oligomers to monomers or dimers will rapidly bind to single-stranded DNA to inhibit HIV-1 replication through a deaminase-dependent
mechanism. A3 proteins deaminate deoxycytidines to deoxyuridines in single-stranded DNA reverse transcription intermediates resulting in G / A hyper-
mutation. In addition, A3 proteins are able to inhibit HIV-1 replication through deaminase-independent mechanisms by interacting with viral nucleocapsid (NCp7)
to reduce tRNA priming and by directly interacting with HIV-1 reverse transcriptase resulting in reduced enzyme activity and processivity. Together these ac-
tivities result in a decrease in the accumulation of HIV-1 reverse transcripts. (4) A3s are also able to interact with HIV-1 integrase to prevent proviral DNA formation
and integration. In the producer cells following integration, the proviral genome is transcribed to produce progeny virion genomes, as well as templates for viral
protein expression. (5) A3 proteins exist in the producer cell as active low-molecular mass (LMM) or inactive high-molecularmass (HMM) protein-RNA complexes.
HIV-1 Vif recruits a E3-ubiquitin ligase complex, composed of EloB/C, cullin 5, core binding factor-b, and Rbx2, to ubiquitinate and target LMM A3 proteins for
proteasomal degradation, thus preventing their encapsidation into nascent virions. (6) In the absence of Vif, LMM A3s interact with progeny virion genomes and
Gag-associated nucleocapsid resulting in their encapsidation during viral assembly. Seven plus or minus four A3molecules are incorporated per virion. Following
(7) release and (8) maturation, the A3 carrying virion will go on to nonproductively infect a target cell.
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Figure 2. Structural Organization and Sequence Alignment of Human APOBEC3 Proteins
(A) Domain organization of human A3 family members. Seven human A3 proteins (A3A, A3B, A3C, A3D, A3F, A3G, A3H) are encoded in a 150 kb region on
chromosome 22. All A3 proteins contain at least one (A3A, A3C, and A3H) or two DNA cytosine deaminase catalytic domains (A3B, A3D, A3F, A3G). The three
phylogenetic clusters of A3 Z domains, Z1, Z2, and Z3 are depicted as orange, blue and green, respectively. The Vif-binding A3 domains were indicated in the
schematic.
(B) Ribbon diagram of A3FC-terminal domain. The overall structural features of each DNA cytosine deaminase domains are very similar between humanA3 family
members. All A3 proteins adopt a common structural fold (a1-b1-b2-a2-b3-a3-b4-a4-b5-a5-a6). The crystal structure of the A3F-CTD (Protein Data Bank [PDB]
codes: 4J4J and 4IOU) represents the Z2-type A3 domains, and it is catalytically active. The zinc ion at the catalytic site, shown in blue, has an important function
during DNA cytosine deamination. The secondary structural elements are depicted as yellow for b sheet, magenta for a helices and light gray for random coil
regions.
(C) Multiple sequence alignment of A3 domains. Each domain of the double-domain A3 proteins (A3B, A3D, A3F, and A3G) is aligned separately and labeled as
the N-terminal (NTD) or C-terminal (CTD) domain. Secondary structure prediction based on the Vif-binding A3F-CTD is depicted above the sequence alignment.
Sequence numbering is based on A3A sequence shown at the top of the alignment. Similar residues are shown in red and outlined withwhite boxes. Residues that
are strictly conserved in all A3 domains are highlighted with red boxes. The sequence alignment was performed by a Clustal W multiple sequence alignment
(Sievers et al., 2011) and plotted using the program ESPript (Gouet et al., 1999).
Structure
Review2005). Other A3 family members, including A3D, A3F, and A3H,
are also expressed in the natural target cells of HIV-1, but
are less potent inhibitors of HIV-1 replication than A3G (Chaipan
et al., 2013; Gillick et al., 2013; Hultquist et al., 2011;Miyagi et al.,
2010; Mulder et al., 2010; Ooms et al., 2013a; Refsland et al.,
2012). In addition to antiviral activities of A3 proteins, recent
evidence by Burns et al. (2013a) suggested that A3B is overex-
pressed in breast cancer cell lines and tumors and is a probable670 Structure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reservedsource of genomic DNA deamination in breast cancer. The role
of A3-mediated mutagenesis in widespread human cancers
has been further characterized and discussed elsewhere (Burns
et al., 2013b; Roberts et al., 2013).
Once a retrovirus binds to a cell receptor via its envelopeglyco-
protein, the viral and host cell membranes either fuse at the
plasmamembrane under neutral pH or the viral particles proceed
through the lowpHendosomal compartments for viralmembrane
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Reviewfusion that will allow the release of core of the retroviral particle
into the cytoplasm (Miyauchi et al., 2009; Stein et al., 1987).
The RNA genome is then reverse transcribed and integrated
into the host genome (Hu and Temin, 1990). Following transcrip-
tion and translation, expressed retroviral proteins migrate to the
cell membrane and assemble into progeny viral particles (Ghey-
sen et al., 1989). In the absence of HIV-1 Vif, A3 proteins in the
cytoplasm bind to the HIV-1 nucleocapsid (NCp7) in a RNA-
dependent manner and are pulled into progeny virions (Cen
et al., 2004; Huthoff and Malim, 2007). These particles carrying
A3proteins are then released from the infected cell. The antiretro-
viral activity of imported A3 proteins, but not thosewhich are pro-
duced in the cytoplasm of newly infected cells, acts within the
reverse transcription complexes to restrict the virus in newly in-
fected cells (Harris et al., 2003; Mangeat et al., 2003; Zhang
et al., 2003). Once an A3-containing virion begins the process
of reverse transcription, the A3 cytosine deaminase activity
acts upon the nascent minus-strand viral cDNAs to deaminate
cytosines to uracils (Yu et al., 2004; Zhang et al., 2003). This ac-
tivity results in the misincorporation of adenines, instead of gua-
nines, in the plus-strand DNA (Yu et al., 2004; Zhang et al., 2003).
Accumulation of G/ A mutations result in stop codons or other
defects that can inhibit infectivity (Lecossier et al., 2003),
although sublethal mutation of proviral genomes has also been
associated with the accelerated development of drug resistance
(Jern et al., 2009; Mu¨nk et al., 2012; Sadler et al., 2010). The
editedDNA intermediatemay be integrated into the host genome
or may have problems completing reverse transcription and
become incompetent for integration (Bishop et al., 2008; Kaiser
and Emerman, 2006); the regulatory events governing these
events are yet to be identified. A3 proteins also exert antiviral
activity independent of DNA cytosine deamination, which in-
volves inhibition of HIV-1 replicative proteins (Newman et al.,
2005). Incorporation of only 7±4A3Gmolecules into the viral par-
ticle is sufficient to hinder viral replication (Xu et al., 2007).
Structural Conservation within the APOBEC3 Family
While there are seven human A3 isoforms, the gross structural
features of the A3 domains are incredibly similar between
proteins, with a characteristic a1-b1-b2-a2-b3-a3-b4-a4-b5-a5-a6
fold (Chen et al., 2008) (Figures 2A and 2B). A prototypical
A3 domain has a core composed of five b sheets, flanked by
six a helices. The degree of similarity comes as no surprise
based on the high degree of primary sequence similarity
(Figure 2C); for example, full-length A3G and A3F have a primary
sequence identity of 50.4%. Root-mean-square deviation (rmsd)
of atomic positions between domains of the A3 family of proteins
is quite low, ranging between 0.7 A˚ to 1.3 A˚. This suggests that
A3 domains adopt a common overall architecture. Despite this
great degree of similarity, it is important to note that some struc-
tural elements subtly differ between familymembers, such as the
interrupted b2 strand of A3G which may have important implica-
tions regarding the conformation and oligomeric state of the full
length A3G protein (Bransteitter et al., 2009; Chen et al., 2008;
Harjes et al., 2009; Holden et al., 2008).
All A3 family members have a conserved (H/C)-(A/V)-E-
(X24–30)-(P-C-X2–4-C) zinc coordination motif that is essential
for DNA cytosine deaminase enzymatic activity (Jarmuz et al.,
2002). A3 proteins are thought to catalyze deamination in aStmechanism analogous to bacterial cytidine deaminases in which
the active site histidine and cysteine residues coordinate the cat-
alytic zinc ion responsible for stabilizing the nucleophilic hydroxyl
generated from a water molecule by the catalytic glutamic acid
(Barnes and Smith, 1993; Betts et al., 1994). This reactive hy-
droxyl nucleophile attacks the C4 atom of the DNA cytosine
base to form a tetrahedral intermediate which collapses into a
ketone group on the pyrimidine ring as the 4-amino group is
lost, thus deaminating the cytosine into uracil (Barnes and Smith,
1993; Betts et al., 1994).
Oligomerization of APOBEC3 Family Proteins
Higher-ordered oligomerization, such asdimerization or tetrame-
rization, is common in the cytidine deaminase family of enzymes.
In the free nucleotide cytidine deaminase subfamily, two different
structural classes have been identified. A homodimeric form,
with two zinc ions per dimer, is primarily restricted to Escherichia
coli and some bacteria (Betts et al., 1994), whereas other organ-
isms adopt a more common square-shaped homotetrameric
formwith four zinc ions per tetramer (Chung et al., 2005; Johans-
son et al., 2002; Song and Neuhard, 1989; Teh et al., 2006). In
contrast, the precise oligomerization state of the APOBEC family
of proteins, which deaminates mRNA and single-stranded DNA,
is poorly defined. Li et al. (2014) revealed that human A2, A3A,
and A3C are monomeric family members, whereas A3B, A3D,
A3F, A3G, and A3H (haplotype II) can form multimeric assem-
blies. Previously, the crystal structure of human A2 has been
used as a model for oligomerization of A3G and other APOBEC
family proteins. The structure of A2 displayed an atypical butter-
fly-shaped tetramer formed by head-to-head interactions of two
A2 dimers (Prochnow et al., 2007). However, this tetrameric
model has been controversial, as other studies using nuclear
magnetic resonance (NMR) and fluorescence fluctuation spec-
troscopy have demonstrated that A2 exists as a monomer in
solution (Krzysiak et al., 2012) and inside the cytoplasm of the
living cell (Li et al., 2014). It has been suggested that the removal
of the first 40 amino acids for crystallization in the A2 crystal
structure led to increased aggregation and formation of a
tetramer (Krzysiak et al., 2012).
A3G has been shown to oligomerize through a number of
biochemical techniques including coimmunoprecipitation, yeast
two-hybrid, and bimolecular fluorescence complementation
studies (Friew et al., 2009; Huthoff et al., 2009; Jaguva Vasude-
van et al., 2013; Opi et al., 2006; Shindo et al., 2003). Moreover,
monomers and larger oligomers of A3G have been detected by
structural and biophysical techniques (Burnett and Spearman,
2007; Chelico et al., 2008; McDougall and Smith, 2011;
McDougall et al., 2011; Shandilya et al., 2010; Shlyakhtenko
et al., 2011; Wedekind et al., 2006). Density gradient centrifuga-
tion studies have also shown that A3G oligomerizes to form both
150–500 kDa low molecular mass (LMM) and 5–15 MDa high
molecular mass (HMM) ribonucleoprotein complexes (Bennett
et al., 2008; Salter et al., 2009; Wedekind et al., 2006). When
they are bound in HMM complexes, A3 antiviral activity is conse-
quently impaired, preventing their encapsidation and DNA
deamination activity (Salter et al., 2009; Soros et al., 2007). In
contrast, their catalytic activity to edit DNA sequences is not
affected when they are in LMM complexes (Chelico et al.,
2006; Salter et al., 2009; Soros et al., 2007; Stopak et al.,ructure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reserved 671
Table 1. HIV-1 Vif Binding Residues in APOBEC3 Proteins
APOBEC3
Vif-Binding Site
Residues References
A3C I72, 75FCxxILS81,
Y86, 106EF107, H111,
P129, E141
Kitamura et al., 2012
A3D-CTD L268, 271FC272,
275ILS277, Y282,
302EF303, H307, E337
Kitamura et al., 2012
A3F-CTD L255, 258FC259,
S264, Y269, F290,
H294, E286, E289,
E316, S320, E324
Albin et al., 2010;
Kitamura et al., 2012;
Siu et al., 2013; Smith
and Pathak, 2010
A3G-NTD 128DPD130 Huthoff and Malim, 2007;
Lavens et al., 2010;
Mangeat et al., 2004;
Schro¨felbauer et al., 2004
A3H haplotype II E121 Ooms et al., 2013b;
Zhen et al., 2010
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indicate that a RNA component is involved in HMM complex for-
mation (Be´langer et al., 2013). Interestingly, amino acids in the
A3G-NTD dimer interface (H65, W94, C97, 24RxxxSxR30 and
122RxYYFW127) exhibit strong RNA binding activity, indicating a
requirement for A3G to bind RNA for head-to-head dimer
formation (Be´langer et al., 2013; Bulliard et al., 2009; Chelico
et al., 2010; Friew et al., 2009; Huthoff et al., 2009). In addi-
tion to A3G-NTD dimerization, it was suggested that A3G
forms higher-order oligomers, such as tetramers, through a
313RIYDDQ318 motif on its CTD in a ‘‘tail-to-tail’’ orientation (Che-
lico et al., 2010). However, the full-length A3G structure has yet
to be determined, thus the interface for multimerization is not
clearly defined. Recently, the relationship between multimeriza-
tion and functional activity of A3 proteins has been characterized
in further detail (Chaurasiya et al., 2014; Li et al., 2014). Using an
optical tweezer assay, Chaurasiya et al. (2014) presented a two-
mode model of A3G binding to single-stranded DNA (ssDNA).
After the incorporation of A3G molecules inside the HIV-1Dvif
virion, A3G protein was suggested to oligomerize on viral RNA
and stall the RT activity during minus-strand synthesis. The
dissociation of A3G oligomers to monomers and dimers allows
for rapid binding and unbinding to single-strand DNA and low
affinity to the RNA-DNA duplex (Chaurasiya et al., 2014). A3G re-
mains in a deamination mode until oligomerization forms a road-
block to stall plus-strand DNA synthesis. These results now shed
some light on how multimerization regulates the deaminase-
dependent and deaminase-independent activity of A3 proteins
and provide a mechanistic explanation to A3 protein function.
Considering the importance of higher-ordered LMM and HMM
protein-RNA complex formation for the antiviral activity of A3
proteins, future studies on the molecular mechanisms of HMM
and LMM formation will provide additional insights into the local-
ization, assembly, and restrictive capabilities of the A3 proteins.
APOBEC3 Vif-Binding Interfaces
The HIV-1 accessory protein Vif neutralizes A3 activity by recruit-
ing an E3 ubiquitin ligase complex (elongin B/C, cullin 5, Rbx2,672 Structure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reservedand core binding factor-b [CBF-b]) to polyubiquitinate A3, thus
targeting it for proteasomal degradation (Ja¨ger et al., 2012;
Sheehy et al., 2003; Zhang et al., 2012) (Figure 1). The evolution-
arily conserved CBF-b is required to stabilize HIV and SIV Vif to
hijack the EloB/C-CUL5-Rbx2 E3 ubiquitin ligase complex (Fri-
bourgh et al., 2014; Guo et al., 2014; Ja¨ger et al., 2012; Zhang
et al., 2012). Intriguingly, attempts to copurify the Vif-binding
domain of A3F with a complex composed of Vif-EloBC-CBF-b
resulted in the displacement of CBF-b (Fribourgh et al., 2014).
This suggests that CBF-bmay be a transient chaperone required
primarily for initial complex assembly and not for prolonged sta-
bility. Moreover, this suggests that the CBF-b-Vif interface may
overlap with A3-Vif.
Recently, elucidation of the structures of several A3 domains
that do (A3F-CTD and A3C) and do not (A2, A3A, and A3G-
CTD) bind to HIV-1 Vif have provided themeans for prudent scru-
tiny and analysis of the existing array of mutagenic data probing
the A3-Vif interface (Byeon et al., 2013; Chen et al., 2008;
Furukawa et al., 2009; Harjes et al., 2009; Holden et al., 2008;
Kitamura et al., 2012; Prochnow et al., 2007; Siu et al., 2013).
Putative Vif-binding residues in various A3 proteins are summa-
rized in Table 1 and Figure 3. Our structural comparison sug-
gests three different modes of Vif binding as described in the
following sections.
A3C/A3F-like Vif-Binding Site
The first structural information of an A3 Vif-binding domain came
from the crystal structure of the single domain A3C (Kitamura
et al., 2012). A series of structure-guided mutagenesis experi-
ments identified ten A3C residues (L72, F75, C76, I79, L80,
S81, Y86, E106, F107, and H111) important for Vif binding,
located within a V-shaped cavity bounded between the a2 and
a3 helices (Kitamura et al., 2012). Recently, two crystal struc-
tures of the A3F Vif-binding domain were reported and revealed
strong structural conservation in the putative Vif-binding site
(Bohn et al., 2013; Siu et al., 2013). A direct protein-protein inter-
action assay using purified recombinant Vif and A3F-CTD re-
vealed that the residues in the V-shaped hydrophobic groove
affected the interaction. However, a role in protein stability is
suggested for residues L255, F258, I262, Y269, and F290 in
the putative A3F-CTD Vif-binding site due to <20% solvent
exposure (Siu et al., 2013). Moreover, hydrophobic A3F-CTD
Vif-binding site mutants are expressed at significantly lower
levels than the wild-type protein, and circular dichroism wave-
length scans revealed differences between the mutant and
wild-type spectra, suggesting secondary structural differences
(Siu et al., 2013).
A large negatively charged cluster (E289, H294, E316, S320,
and E324) is found on a solvent-exposed surface on A3F-CTD,
adjacent to the previously characterized V-shaped hydrophobic
Vif-binding site in A3C (Siu et al., 2013). Given that HIV-1 Vif likely
has significant positive charge on its surface (pI > 10), it is bio-
chemically intuitive that the region of binding on A3 would be
negatively charged. In support of this, alanine-scanning muta-
genesis and analysis by biolayer interferometry revealed that
the negatively charged residues E286, E289, E316, and E324
are critical for Vif binding. Homology modeling and structural
alignments suggest that this negatively charged site is con-
served in A3C, A3D-CTD, and A3F-CTD (Figures 3A and 3B).
Thus, A3C, A3D, and A3F interact with Vif via a negatively
Figure 3. APOBEC3 HIV-1 Vif-Binding Sites
(A) APOBEC3 proteins likely adopt three distinct types of Vif-binding sites: A3C/A3F-like, A3G-like, and A3H-like. Surface electrostatic potential and ribbon
diagrams showing the three classes of A3 Vif-binding sites (yellow dashed lines) are shown. Negatively and positively charged regions are shown in red and blue,
respectively. The A3C/A3F-like class is represented by A3C (PDB code: 3VOW), A3F-CTD (PDB codes: 4J4J and 4IOU) and A3D-CTD (homology model). The
A3G-like and A3H-like classes are represented by homologymodels of the A3G-NTD and A3H, respectively. In A3C, A3F-CTD, and A3G-NTD, residues shown as
red sticks in the ribbon diagrams represent experimentally determined Vif binding residues. Based on the A3F-CTD Vif-binding site, conserved residues are
identified as red sticks in the A3D-CTD and A3H haplotype II homology models. Equivalent regions of the non-Vif binding A2 (PDB code: 2NYT) and A3A (PDB
code: 2M65) show charge reversal and reduced hydrophobicity compared to the other A3 Vif-binding domains, thus potentially explaining its lack of Vif binding
ability.
(B) Schematic showing the conservation of critical residues involved in HIV-1 Vif binding for A3 proteins. The positions of secondary structural elements are shown
in the figure. Experimentally determined Vif-binding residues are shown in A3C, A3F-CTD, and A3G-NTD, whereas in A3D-CTD and A3H only the equivalent
residues that are conserved with A3F-CTD are shown (with the exception of E91 in A3H).
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Reviewcharged patch on the a2, a3, and a4 helices. The negatively
charged residues identified by Siu et al. are consistent with the
recently determined Vif-CBF-b-EloB/C-CUL5 pentameric crystal
structure (Guo et al., 2014). A positively charged surface on Vif is
solvent exposed and in an ideal structural location to position A3
for ubiquitination (Figure 4).
A3G-like Vif-Binding Site
A3G binds HIV-1 Vif through its N-terminal domain and appear to
involve a surface distinct from the A3C/A3F-like Vif-binding siteSt(Figure 3A). The negatively charged residues in the a2, a3, and
a4 helices implicated in A3C and A3F-CTD Vif-binding are poorly
conserved in A3G-NTD. In fact, surface electrostatic potential
calculations of a homology model of A3G-NTD suggest a charge
reversal compared to the equivalent A3C/A3F-like Vif-binding
sites (Figure 3A). Moreover, mutating residues in A3G-NTD that
correspond to the A3C/A3F-like Vif-binding site revealed no
change in the Vif-sensitivity profile (Kitamura et al., 2012). There-
fore, it is thought that A3G binds Vif in an alternate manner.ructure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reserved 673
Table 2. Summary of A3-Binding Residues in HIV-1 Vif
A3 Protein Vif A3-Binding Residues References
A3G Binding
Vif-N-terminal 30Yx9YRHHY
44 Chen et al., 2009
40YRHHY44 Russell and Pathak, 2007
I9 Wichroski et al., 2005
W21, S32, W38, Y40, H43 Yamashita et al., 2008
H42, H43 Mehle et al., 2007
N48 Russell and Pathak, 2007
residues 8–45 Reingewertz et al., 2013
Vif-middle 55VxIPLx4-5LxFx2YWxL
72 Chen et al., 2009
residues 83–99 Reingewertz et al., 2013
residues 73–99 Santa-Marta et al., 2005
residues 96–107 Dang et al., 2010a
Vif-C-terminal 161KPPL164 Donahue et al., 2008
residues 154–192 Reingewertz et al., 2013
residues 169–192 Santa-Marta et al., 2005
A3F Binding
Vif-N-terminal 11WQVDRMR17 Russell and Pathak, 2007
W11 Tian et al., 2006
Vif-middle 55VxIPLx4-5L
64 Chen et al., 2009;
He et al., 2008
74TGERxW79 He et al., 2008
Vif-C-terminal 171EDRWN175 Dang et al., 2010b
A3G/A3F Binding
21WxSLVK26 Yamashita et al., 2008
Dang et al., 2009
69YxxL72 Pery et al., 2009
81LGQGVSIEW89 Dang et al., 2010b
Y69 Yamashita et al., 2008
G84 Dang et al., 2010b
A3H (Haplotype II) Binding
39FH40 Binka et al., 2012
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128DPD130 motif in A3G, located in the loop between b5 and
a6, is important in Vif binding (Lavens et al., 2010). The negatively
charged surface encompassing the 128DPD130 motif is likely a
key determinant for A3G-Vif binding as it is able to interact
with the exposed positively charged surface on Vif (Guo et al.,
2014).
Other A3 Vif-Binding Sites
A3H belongs to a Z3-type deaminase domain andmay exemplify
a third class of A3 Vif-binding domains. Homology modeling
of A3H haplotype II reveals a complete charge reversal in
the A3H region that corresponds to the negatively charged
128DPD130 motif in the A3G-NTD (Figure 3A). The negatively
charged region in A3F-CTD that interacts with Vif is fairly well
conserved in A3H, however, the hydrophobic residues are poorly
conserved, further supporting the model that electrostatic inter-
actions between A3 and Vif are important. Moreover, the surface
electrostatic potentials show that the Vif-binding site is less
negatively charged in A3H than in any of the A3C/A3F-like Vif-
binding sites. This agrees well with studies demonstrating that674 Structure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reservedVif isoforms encoded by most HIV-1 isolates have a reduced
affinity for A3H, when compared to other A3 proteins (Hultquist
et al., 2011).
HIV-1 Vif APOBEC3-Binding Site
Recently, the crystal structure of HIV-1 Vif in complex with
EloB/C, CBF-b, and the N-terminal domain of CUL5 was deter-
mined (Guo et al., 2014). However, this structure lacks its A3
protein substrate. Previous biochemical studies have identified
a number of motifs that are involved in A3 protein binding
(summarized in Table 2). Of note, mutation of the 40YRHHY44
Vif motif is sufficient to prevent the degradation of A3G without
eliminating proteasomal degradation of other A3 proteins and
conversely mutation of 14DRMR17 confers a Vif phenotype that
is capable of degrading A3G, but not A3F or A3D (Chaipan
et al., 2013). This suggests these two patches of Vif are neces-
sary for degradation of their respective A3 binding partners but
alonemay not be sufficient tomediate degradation. The A3 bind-
ing motifs are clustered to three primary regions localized to
N-terminal, middle, and C-terminal parts of HIV-1 Vif. Mapping
these residues onto the surface of the HIV-1 Vif structure illus-
trates two distinct A3 protein-binding surfaces (Figure 4). The
A3G- and A3F-binding sites appear to be on opposite sides of
Vif. Interestingly, it appears that CBF-b may mask part of the
A3F binding motif. This is consistent with recent studies that
show the displacement of CBF-b is necessary for the recruitment
of A3F to the E3 ubiquitin ligase complex (Fribourgh et al., 2014).
In contrast, the Vif A3G-binding site is likely fully accessible
(Figure 4). It is becoming more apparent that HIV-1 Vif has
evolved to utilize disparate binding surfaces as a common solu-
tion to recognize different A3 proteins.
APOBEC3-DNA Interactions
The recently described A3A, A3G, and A3F high-resolution struc-
tures in combination with mutational studies or real-time NMR
titrations led to several proposed mechanisms by which A3 pro-
teins bind DNA (Bohn et al., 2013; Byeon et al., 2013; Chen et al.,
2008; Furukawa et al., 2009; Holden et al., 2008; Siu et al., 2013).
A summary of the ssDNA-binding residues and modes in avail-
able A3 proteins is presented in Table 3 and Figure 5.
A3G DNA-Binding Modes
Three disparate models exist for the binding of ssDNA to A3G
(Figure 5A). NMR DNA titration experiments suggest a ‘‘brim’’
model in which binding is primarily mediated by positively
charged and aromatic residues on the brim of a negatively
charged groove formed by loops 1, 4, and 5, and helices a1
and a2 (Chen et al., 2008). In this model, the DNA runs 50 / 30
from the N toC terminus along the alpha helices. Real-timemoni-
toring of the deamination reaction by NMR supports a similar
model, the so-called ‘‘straight’’ model with a greater degree of
involvement of the a1, a2, and a4 helices, although the polarity
of the DNA is ambiguous in this model (Furukawa et al., 2009).
The ‘‘kinked’’ model of DNA binding suggests that ssDNA inter-
acts predominately with a series of arginine and aspartic acid
residues lining helix a6 and loops 1, 2, 5, and 6, as well as residue
244, an asparagine which is conserved across all free cytidine
deaminases (Holden et al., 2008) (Figure 5A).
There is little overlap in the residues in A3G identified as critical
by any two of these models and no overlap among all three. But,
Figure 4. HIV-1 Vif APOBEC3-Binding Sites
(A) Structure of the HIV-1 Vif-CBF-b-EloB/C-CUL5
pentameric complex (PDB code: 4N9F). CBF-b,
CUL5, and EloB/C are shown in a ribbon diagram,
whereas HIV-1 Vif is depicted with its molecule
surface. Defined HIV-1 Vif motifs previously shown
to be necessary for A3G, A3F, or A3G/A3F binding
are mapped onto Vif and colored in red, yellow and
orange, respectively. The putative location of the
missing A3G, C-terminal domain of CUL5, Rbx2,
and E2 are shown as spheres.
(B) Molecular surface of HIV-1 Vif illustrates two
distinct binding surfaces for A3G and A3F. The
A3F-binding surface is on the opposite side (180
away) from the A3G-binding interface. The pres-
ence of CBF-b on HIV-1 Vif partially restricts the
A3F-binding site. The displacement of CBF-b may
be necessary for the recruitment of A3F to the
Vif-E3 ubiquitin ligase complex. The orientation of
HIV-1 Vif in the left hand figure is in the same
orientation as in (A).
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the straight and brim models are proximal to each other in
primary sequence and were identified using two different A3G-
CTD constructs suggesting they are not likely to be artifacts of
mutations made to increase soluble expression. Additionally, it
is important to keep in mind that these models were based on
analysis of an incomplete monomeric unit and that the models
may be correct at various times as A3G adopts differing oligo-
meric states, or in the context of the protein containing both
domains. At this point, there is insufficient data to conclusively
determine which or whether all of these models are correct.
The precise ssDNA binding mode may remain unknown until
the structure of an A3 protein in complex with ssDNA is
determined.
A3A and A3F DNA-Binding Modes
Real-time NMR and molecular docking studies suggest that the
A3A residues that bind ssDNA form a groove along the N-termi-
nal ends of the a2, a3, and a4 helices and involve loops 3 and 7
residues. 103SWG105, D13, L135, and E138 (Byeon et al., 2013)
are the key residues in ssDNA binding. The A3A ssDNA-binding
groove is similar to the kinked model proposed for the A3G-
CTD binding to ssDNA (Figure 5B). Intriguingly, the model for
DNA binding of the closely related A3F protein is somewhat
different (Siu et al., 2013). Mutagenic and structural data suggest
a model in which the ssDNA is bound by a groove running
along the a4 and a6 helices with interactions to residues in loops
1, 3, and 7. Mutations to W277, R305, K367, Q369, andStructure 22, May 6, 2014307YYFxxxDY314 greatly reduced ssDNA
affinity (Siu et al., 2013). The ssDNA-bind-
ing groove in A3F-CTD is consistent with
the ‘‘straight’’ groove model of A3G-CTD
(Siu et al., 2013) (Figure 5C).
A3 Substrate Specificity
A3 proteins generally have one of two sub-
strate specificities with the prototypical
examples being the preference of A3G
for a 50-CC-30 sequence and that of A3F
for 50-TC-30 or 50-GC-30 sequences (Harris
et al., 2002; Liddament et al., 2004;
Rausch et al., 2009; Siu et al., 2013).Numerous attempts at structural explanations for substrate
specificity have been made based on data from mutagenesis
studies, NMR substrate titration, molecular docking studies,
and real-time NMR monitoring of the deamination reaction
(Byeon et al., 2013; Chen et al., 2008; Holden et al., 2008; Siu
et al., 2013). The recently proposed ‘‘aromatic switch’’ model,
which is based on aromatic residues in loops proximal to the
active site forming base stacking interactions with substrate
DNA, is most compelling given mutagenesis experiments that
demonstrated a complete transfer of substrate specificity from
A3G to A3F when the nucleotide specificity boxes composed
of 307YYFW310 and 315YDDQ318 in A3F-CTD and A3G-CTD,
respectively, are switched (Carpenter et al., 2010; Holden
et al., 2008; Kohli et al., 2009; Siu et al., 2013). The nucleotide
specificity box loop regions of A3G-CTD and A3A can also be
exchanged to alter specificity (Rathore et al., 2013). The aromatic
switch model is also supported by molecular docking studies
based on real-time monitoring of the A3A deamination reaction
(Byeon et al., 2013).
A3 Nucleotide Processivity
A3G deaminase activity has been shown to act processively in
the 30 / 50 direction (Chelico et al., 2006). A3G is defined as
processive because of its ability to deaminate multiple DNA
cytosine nucleotides on ssDNA. Upon binding ssDNA, A3G
scans the DNA in either direction for its recognition sequence
(Chelico et al., 2006; Feng and Chelico, 2011). A3G can bind
any region of a ssDNA molecule in one of two conformations,ª2014 Elsevier Ltd All rights reserved 675
Table 3. ssDNA-Binding Residues in APOBEC3 Proteins
APOBEC3 Residues References
A3A N57, H70, E72, 102FSWG105,
D133, L135, E138
Byeon et al., 2013
A3F W277, 305RxYYFW310, 313DY314,
K367, Q369
Siu et al., 2013
A3G: brim
model
213RxR215, 254ExR256, E259,
W285, C288, C291, 313RIY315,
R320, H367
Chen et al., 2008
A3G: straight
model
196SxD198, F204, N208, R215,
R238, G240, 242LC243, A246,
254ExRH257, 260LCFLxVI266,
271LDxDQ275, R278, 283TS284,
305VS306, D316, G319, I337,
D348, 351VD352, D362
Furukawa et al.,
2009
A3G: kinked
model
211WxR213, H216, N244, H257,
W285, 313RxYDDQ318, R320,
374RxR376
Holden et al.,
2008
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Reviewan active conformation in which the CTD faces 50 or an inactive
conformation wherein the CTD face 30 with equal probability,
suggesting ssDNA polarity is not an important factor (Senavir-
athne et al., 2012; Shlyakhtenko et al., 2012). This phenomenon
may be responsible for the 30/ 50 directionality of themutational
gradient characteristic of A3G. A recent publication suggests an
alternate model in which differences in deamination efficiency,
based upon the direction of approach to the deaminated recog-
nition sequence by A3G, are responsible for this mutational
gradient (Furukawa et al., 2014). The real-time NMR data sup-
porting this model is quite compelling, however, it does not
rule out the possibility that A3G can bind DNA in multiple modes.
Upon reaching a recognition sequence, A3G has been shown to
hover near that sequence via a biased sliding movement and
cause DNA contraction prior to catalysis (Senavirathne et al.,
2012). A3G can surpass a double-stranded barrier by ‘‘hopping’’
over several nucleotides to gain access to another region of the
same ssDNA molecule (Chelico et al., 2006). The noncatalytic
NTD motif 126FW127 has been shown to be crucial for hopping
activities (Feng and Chelico, 2011). In contrast, A3A displays
significantly reduced processivity during deamination of syn-
thetic ssDNA substrates in vitro (Love et al., 2012). It is not clear
whether other A3 family proteins are processive or not.
APOBEC3-RNA Interactions
A3 proteins exhibit RNA binding properties to form higher-
ordered A3 assemblies and to interact with HIV-1 viral proteins
during replication (Be´langer et al., 2013; Cen et al., 2004; Huthoff
et al., 2009). A3G binds to a variety of host and viral RNAs, such
as HIV-1 viral RNA, 7SL RNA, hY1, hY3, hY4, hY5, and Alu
element RNA through its NTD (Bach et al., 2008; Bulliard et al.,
2009; Huthoff et al., 2009; Khan et al., 2007; Wang et al.,
2008). A large pocket within A3G-NTD was identified as both a
RNA binding and oligomerization site (Huthoff et al., 2009).
Mutations to critical residues forming this pocket in both the
A3G-NTD (R24, R30, H65,W94, C97, Y124, andW127) (Figure 6)
and A3C (R122) resulted in reduced packaging and impaired
antiviral activity due to inefficient RNA binding (Be´langer et al.,
2013; Bulliard et al., 2009; Friew et al., 2009; Huthoff et al.,676 Structure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reserved2009; Stauch et al., 2009). With the exception of R24 and
W127, these residues are conserved in all A3 domains, indicating
that a common RNA binding site might be conserved across A3
proteins.
APOBEC3 Deaminase-Independent Antiviral Activities
A3 activity encompasses manymeans to exhibit broad antiretro-
viral activity. While DNA cytosine deamination was initially
thought to be the sole mechanism responsible for this antiretro-
viral activity, several lines of evidence demonstrated the
presence of a deamination-independentmode of retrovirus repli-
cation inhibition and indicated a dual mechanism of action
providing more effective restriction of retroviruses (Bishop
et al., 2006; Iwatani et al., 2007; Newman et al., 2005). A3 pro-
teins can restrict the infectious activity of retroviruses in the
absence of discernible DNA editing activity (Bishop et al.,
2006; Holmes et al., 2007). Direct or RNA-mediated interactions
between A3 proteins and (1) nucleocapsid (NCp7), (2) reverse
transcriptase (RT), and (3) integrase (IN) proteins have been
observed in in vitro assays and are hypothesized to play a role
in the noncatalytic activity of the A3 proteins in vivo (Figure 6)
(Cen et al., 2004; Guo et al., 2007; Luo et al., 2007; Wang
et al., 2012).
Encapsidation and Nucleocapsid Interactions
The incorporation of A3G proteins into Vif-lacking progeny HIV-1
virions during particle assembly requires specific RNA-depen-
dent interactions with NCp7 (residues 378–433) and strongly
correlated with lipid raft association (Burnett and Spearman,
2007; Cen et al., 2004; Khan et al., 2005, 2009) (Figures 6A and
6B). The linker region between two zinc fingers of NCp7 contains
a positively chargedmotif, 406RxxRKK411 that is involved in bind-
ing to A3G (Burnett and Spearman, 2007; Guo et al., 2007; Luo
et al., 2004). Likewise, A3G residues 104–156 between the two
zinc coordination motifs mediate the interactions with NCp7 for
incorporation into progeny virions (Cen et al., 2004). More specif-
ically, a 124YYFW127 motif was shown to be important for A3G
encapsidation (Huthoff and Malim, 2007). Based on the homol-
ogy model of the A3G-NTD, the 124YYFW127 motif resides on
the surface and is adjacent to a negatively charged motif
(128DxDYxxE133). The 128DxDYxxE133 motif corresponds to the
only apparent negatively charged surface within residues 104–
156 of A3G-NTD, and is hypothesized to be complementary to
the positively charged nature of the NCp7 motif. Interestingly,
positively charged and hydrophobic motifs on HIV-1 Vif were
also shown to bind to the 128DxDYxxE133 motif (Cen et al.,
2004; Huthoff and Malim, 2007; Letko et al., 2013), suggesting
both Vif and NCp7 might utilize a similar surface for interaction
with A3G. Furthermore, both A3G and NCp7 are RNA-binding
proteins and the positively charged residues (406RxxRKK411)
within the NCp7 linker region that is involved in binding to A3G
were also shown to increase the RNA content of viral particles
(Burnett and Spearman, 2007). Therefore, it is important to
mention that a RNA bridge composed of cellular or viral RNAs
may facilitate the interactions between the two proteins and
allow the incorporation of A3G into the progeny virions (Burnett
and Spearman, 2007).
In the target cells, NCp7 facilitates the annealing of HIV-1
tRNA3
Lys to the primer binding site to initiate reverse transcrip-
tion (Guo et al., 2009; Saadatmand et al., 2009). Annealing of
Figure 5. APOBEC3 DNA-Binding Sites
Multiple models of single-stranded DNA binding have been observed in
A3 proteins. NMR titration and X-ray crystal structures combined with
mutagenic studies have revealed at least two models of DNA binding in the
A3G-CTD.
(A) A molecular surface of A3G-CTD (PDB codes: 3IR2, 2JYW, 3EIU, 2KBO) is
presented with the directionality of the ssDNA of the two DNA binding models.
A ‘‘kinked’’ model as proposed by Holden et al. (2008) is shown by a solid
green line, whereas a ‘‘brim’’ or ‘‘straight’’ model, as proposed by Furukawa
et al. (2009) and Chen et al. (2008) is displayed by a blue line. Key residues
proposed by the brim or straight model are colored blue and white, respec-
tively, while residues implicated in DNA binding by the kinkedmodel are green.
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ReviewtRNA3
Lys to viral RNA requires positively charged residues
(384RxxRKxxK391 and 406RxxRKK411) flanking the N-terminal
zinc finger of NCp7 (Guo et al., 2007). Although A3G does not
directly interfere with the tRNA3
Lys annealing by competitively
binding to viral RNA, it does inhibit tRNA3
Lys annealing through
interactions with NCp7 (Guo et al., 2006, 2007, 2009). On the
other hand, Iwatani et al. (2007) suggested that A3G does not
interfere with tRNA3
Lys annealing, but instead suppresses the
extension of tRNA3
Lys to hinder the () ssDNA synthesis primed
by tRNA3
Lys. The NCp7 region involved in tRNA annealing over-
laps with the A3G binding site, therefore, it is predicted that the
ability of A3G to bind to NCp7 results in the inhibition of NCp7-
facilitated tRNA3
Lys annealing to viral RNA or the reduction of
tRNA3
Lys primer extension required for () ssDNA synthesis
(Burnett and Spearman, 2007; Guo et al., 2007; Iwatani et al.,
2007; Luo et al., 2004).
Reverse Transcription
A3 proteins may also interfere with HIV-1 RT independently of
deaminase activity (Bishop et al., 2006; Newman et al., 2005), re-
sulting in the inhibition of initiation of DNA synthesis (Yang et al.,
2007), initiation of primer extension (Adolph et al., 2013), minus-
and plus-stand transfer (Li et al., 2007), DNA elongation (Bishop
et al., 2008), enzyme processivity (Gillick et al., 2013), and accu-
mulation of reverse transcription products (Be´langer et al., 2013;
Holmes et al., 2007; Iwatani et al., 2007). Both A3G and A3F
inhibit the accumulation of HIV-1 transcripts in the absence of
DNA editing (Gillick et al., 2013; Holmes et al., 2007; Iwatani
et al., 2007; Yang et al., 2007). Interestingly, inactivation of the
C-terminal DNA cytosine deaminase motif of A3G (E259Q) re-
vealed a profound decrease on the antiviral activity of A3G sug-
gesting a much greater role for DNA editing in viral inhibition
in vitro (Holmes et al., 2007). However, the A3G E259Q mutant
was also shown to have a lower affinity to bind the RNA template
and reduced ability to inhibit cDNA accumulation compared to
wild-type A3G (Adolph et al., 2013; Bishop et al., 2008). These re-
sults suggest that disruption of the A3GC-terminal DNA cytosine
deaminase motif may decrease the RNA binding abilities of A3G
and attenuate the A3G-mediated inhibition of cDNA accumula-
tion in vitro (Adolph et al., 2013; Bishop et al., 2008). It is yet un-
clear whether the A3G E259Qmutant has an effect on the protein
structure and in vivo function. In contrast, catalytically inactive
A3F shows only a slight reduction in reverse transcript accumu-
lation and antiviral activity compared to the wild-type protein
in vitro (Bishop et al., 2006; Holmes et al., 2007; Yang et al.,
2007). This indicates that for some A3 proteins the cytosine
deaminase activity has the primary antiviral effect, but for others
the deaminase-independent activities are more critical for the
initial restriction of HIV replication.
While A3G and A3F are known to restrict the accumulation of
viral cDNA, themechanisms underlying this activity aswell as the
physical and functional interaction between the A3s and RT
requires more thorough characterization. It was hypothesized(B) In A3A (PDB code: 2M65), the ssDNA appears to bind along a ‘‘kinked’’
groove similar to the Holden et al. (2008) model in A3G-CTD. Experimentally
identified residues that are important in A3 ssDNA binding are presented in
Table 3.
(C) In A3F-CTD (PDB code: 4J4J), ssDNA binds along a ‘‘straight’’ groove
similar to the observed model by Furukawa et al. (2009) and Chen et al. (2008)
in A3G-CTD.
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Figure 6. Deamination-Independent Interactions of APOBEC3G
(A) Schematic representations of the HIV-1 Gag, RT, IN, and A3G proteins. Numbers above the schematics indicate the amino acid positions for each domain of
the Gag, RT, IN, and A3G proteins. Regions in HIV-1 Gag, RT, and IN that interact with A3G are labeled in blue, orange, and green, respectively. The catalytic DNA
cytosine deaminase domain of A3G is shown in red. The A3G residues responsible for dimer formation, DNA cytosine deamination, substrate specificity, and
RNA, DNA, NC, RT, IN, Vif interactions are labeled on the A3G schematic. Abbreviations are as follows: Gag, group-specific antigen; RT, reverse transcriptase; IN,
integrase; MA, matrix; CA, capsid; p2, spacer peptide 1; NC, nucleocapsid; p1, spacer peptide 2; p6, p6-Gag protein; NTD, N-terminal domain; CCD, core
catalytic domain; CTD, C-terminal domain; A3G, APOBEC3G; CDD1, cytosine deaminase domain 1; CDD2, cytosine deaminase domain 2; Vif, viral infectivity
factor.
(B) Surface electrostatic potential and ribbon diagram of a homology model of the A3G-NTD. The A3G-NTD homology model was generated using the Phyre2
protein fold recognition server (Kelley and Sternberg, 2009). A negatively charged surface (showed in blue dash lines) was proposed to be the NCp7 binding site.
The 128DPD130 motif involved in A3G Vif binding is highlighted with a yellow dashed line. A positively charged surface illustrates the footprint of the A3G-NTD
residues (black dash lines) necessary for RNA binding and ‘‘head-to-head’’ dimer formation.
(C) Molecular surface of the homologymodel of the A3G-NTD. HIV-1 RT and IN binding sites on A3G-NTD are colored as orange and green surfaces, respectively.
Surfaces that overlap between the HIV-1 RT and IN binding sites are shown as a pink surface. Residues on the surface of A3G-NTD that may play a role in HIV-1
RT and IN interactions are shown as sticks colored according to the molecular surface. Interestingly, parts of the 128DPD130 Vif-binding residues and NCp7
binding site residues also converge on the overlap regions between the HIV-1 RT and IN binding sites (yellow dashed lines).
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Reviewthat when A3 proteins are bound to viral RNA or ssDNA, they
block RT movement along the template; hence, resulting in re-
ductions of viral reverse transcription products (Chaurasiya
et al., 2014; Gillick et al., 2013). Using a cell-based coimmuno-
precipitation assay, Wang et al. (2012) showed that the A3G
amino acids 65–132 are responsible for the direct interaction be-
tween A3G and HIV-1 RT (Figures 6A and 6C). Their data also
suggested that A3G binds to the N-terminal RT fingers and
palm domains (residues 1–243) (Wang et al., 2012) (Figures 6A
and 6C). This direct interaction occurs in the absence of both
HIV-1 IN and RNA bridging (Wang et al., 2012). In the absence
of the HIV-1 Vif protein, approximately seven (±4) A3Gmolecules
were estimated to incorporate into each virion, and only a few
A3G molecules are sufficient to inhibit HIV-1 replication in target
cells (Xu et al., 2007). However, each HIV-1 virion contains 100
RT heterodimers (Coffin et al., 1997), which is ten times more
than the number of A3G molecules inside the HIV-1Dvif virion,
suggesting that direct A3G-RT interaction may not be the sole
mechanism for A3G-mediated reverse transcription inhibition678 Structure 22, May 6, 2014 ª2014 Elsevier Ltd All rights reserved(Adolph et al., 2013; Chaurasiya et al., 2014). It has recently
been shown that A3G oligomers bind tightly to ssDNA (Chaura-
siya et al., 2014). This tight binding of A3G may block RT move-
ment along the template, hence resulting in a reduction of viral
DNA synthesis (Chaurasiya et al., 2014). These results clearly
indicate that A3 oligomerization might be a critical factor for
deaminase-independent restriction of viral replication (Chaura-
siya et al., 2014).
Integration
Mounting evidence suggests that A3G and A3F impair viral DNA
integration via distinct mechanisms (Be´langer et al., 2013; Luo
et al., 2007; Mbisa et al., 2007, 2010). A3G encounters viral
DNA in the cytoplasm, and the interaction results in the formation
of a 6-nucleotide extension at the U5 end of the viral DNA (Mbisa
et al., 2007). These atypical viral DNA ends interfere with the host
cell genome integration and decrease the proviral DNA formation
(Mbisa et al., 2007). On the other hand, A3F hinders viral DNA
integration by reducing the efficiency of 30 processing at both
viral DNA ends (Mbisa et al., 2010). Despite both proteins
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Reviewsuccessfully interfering with HIV-1 DNA integration, DNA cyto-
sine deamination activity was only shown to be critical for the
A3G-mediated inhibition of viral DNA integration, but not for
A3F (Mbisa et al., 2007, 2010). This potent deamination-indepen-
dent activity of A3F contributes to the antiviral function of the
protein to a greater extent than the A3G-mediated inhibition
and amplifies the inhibition of viral DNA integration and replica-
tion (Mbisa et al., 2010).
A3G interacts with HIV-1 integrase in a RNA-dependent
manner (Luo et al., 2007). The A3G-NTD amino acids between
104 and 156 bind the CTD of integrase (residues 212–288) and
block the proviral DNA formation in vitro (Luo et al., 2007) (Fig-
ures 6A and 6C). A3F also binds to IN and hinders the integration
of the viral DNA in vitro (Luo et al., 2007). However, the single
domain A3C does not interact with IN or interfere with viral
DNA integration, highlighting major differences among A3 family
members (Luo et al., 2007). Surprisingly, parts of the A3G inte-
grase-binding region overlaps with the Vif-binding, NCp7-bind-
ing, and RT-binding regions (Cen et al., 2004; Huthoff andMalim,
2007; Letko et al., 2013; Luo et al., 2007; Wang et al., 2012)
(Figure 6C). We speculate that from the initial stages of viral
assembly to viral DNA integration, amino acids 65–156 in NTD
of A3G are the key residues that interact with HIV-1 proteins
Vif, NCp7, RT and IN to confer deamination-independent activity
in vitro. The existence of A3 proteins in the retrovirus replication
cycle may exert a multifaceted antiviral effect and even slight re-
ductions at each step may generate a strong synergistic activity
that blocks the production of nascent viral particles in cells.
Future studies focusing on determining the atomic resolution
structures of A3 and HIV-1 protein complexes, and functional
characterization of these interactions using in vivo models will
allow us to establish the boundaries of A3-mediated deami-
nase-independent antiviral activity.
Strategies for Therapeutic Applications: Concluding
Remarks
Although the availability of antiretroviral therapies has signifi-
cantly increased the life expectancy of those living with HIV/
AIDS, drug resistance compromises the effectiveness of current
therapeutics (Ketseoglou et al., 2013; Kumar et al., 2014; Li et al.,
2012; Masimba et al., 2013; Thiam et al., 2013). Additionally,
many drug regimens currently employed to treat HIV/AIDS result
in substantial side effects, such as lypodystrophy, hyperglyce-
mia, liver failure, and cardiovascular diseases (Carr and Cooper,
2000; Kalayjian et al., 2012; Max and Sherer, 2000; Towner et al.,
2012). Novel therapeutics are necessary to offer alternative treat-
ment options to those living with HIV/AIDS. Therapies targeting
cellular proteins or proteins at the host-pathogen interface are
intriguing as these targets should be less prone to mutations,
which result in resistance. In the case of A3, the goal of a thera-
peutic strategy would be to increase the levels of A3 proteins
incorporated into nascent HIV-1 virions.
Structural studies of A3 proteins have been challenging due to
difficulties in expressing soluble protein. However, recent struc-
tures of A3A, A3C, A3F-CTD, and A3G-CTD now provide key
understandings into recognition of ssDNA and HIV-1 proteins
and thus an initial blueprint to identify potential sites for thera-
peutic intervention. The recent crystal structure of the Vif-CBF-
b-EloB/C-CUL5 pentameric complex revealed that developingStinhibitors against the Vif-CBF-b interface has potential chal-
lenges, as the Vif-binding surface on CBF-b overlaps with its nat-
ural cotranscriptional binding partner, RUNX1. The Vif-ubiquitin
ligase interface has also been proposed as targets (Zuo et al.,
2012), however, targetable regions that differ from interfaces
necessary for function of native cellular cullin-RING ligase com-
plexes may be difficult to identify and specifically target. A ther-
apeutic strategy that disrupted the Vif-CBF-b-EloB/C-CUL5
pentameric complex but retained the Vif-A3G interaction, led
to inefficient restriction of HIV-1 replication (Feng et al., 2013).
Therefore, we suggest that the A3-Vif interface is a compelling
drug target. Inhibition of the interaction between Vif and A3
would prevent the degradation of A3 and enhance its antiviral
activity. Inhibitors would need to be carefully designed to not
impair the packaging of A3 proteins in nascent HIV-1 virions.
This is particularly important in the case of the A3G-Vif interface,
as the Vif-binding 128DPD130 motif in A3G-NTD is proximal to the
RNA and NCp7 binding sites involved in virion encapsidation.
However, in the A3C/A3F-like Vif-binding sites, the hydrophobic
and negatively charged Vif-binding surface is distinct from the
ssDNA-binding site and regions involved in encapsidation, which
may aid in the development of inhibitors that do not impede anti-
viral activity.
Several small molecule inhibitors targeting the Vif-A3 axis
(Cen et al., 2010; Xiao et al., 2007) have been developed, most
notably is the molecule RN-18 that was shown to enhance Vif
degradation, increase the abundance of A3G, A3F, and A3C
leading to inhibited replication of HIV-1 in cultured cells (Nathans
et al., 2008). Several other compounds protecting A3G from
proteasomal degradation have also been identified (Cen et al.,
2010). Development of inhibitors targeting the A3-Vif is feasible,
but the in vivo efficacy of these inhibitors remains to be
demonstrated.
Once the mechanisms and role of A3 deaminase-independent
restriction are fully elucidated, they may offer targets for drug
design against HIV-1 RT and IN interactions. In conclusion,
structural studies that elucidate the structure-function relation-
ships between A3 and HIV viral proteins are critical in order for
us to understand the ways in which HIV-1 is able to manipulate
its host.
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